New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 15, 2013
10:03 EDTDUK, GMCR, CVE, FTI, SYMC, VPHM, RPM, RAS, PDH, MLNX, MXIM, CS, CLF, CELG, BSXOn The Fly: Analyst Upgrade Summar
Today's noteworthy upgrades include: Boston Scientific (BSX) upgraded to Outperform from Neutral at Credit Suisse... Celgene (CELG) upgraded to Buy from Neutral at BofA/Merrill... Cliffs Natural (CLF) upgraded to Buy from Hold at Deutsche Bank... Credit Suisse (CS) upgraded to Outperform from Neutral at Exane BNP Paribas... Maxim Integrated (MXIM) upgraded to Outperform from Perform at Oppenheimer... Mellanox (MLNX) upgraded to Buy from Neutral at UBS... PetroLogistics (PDH) upgraded to Buy from Neutral at Citigroup... RAIT Financial (RAS) upgraded to Outperform from Market Perform at FBR Capital... RPM (RPM) upgraded to Perform from Underperform at Oppenheimer... ViroPharma (VPHM) upgraded to Buy from Neutral at BofA/Merrill... Symantec (SYMC) upgraded to Overweight from Equal Weight at Morgan Stanley... FMC Technologies (FTI) upgraded to Overweight from Equal Weight at Morgan Stanley... Cenovus Energy (CVE) upgraded to Overweight from Neutral at JPMorgan... Green Mountain (GMCR) upgraded to Buy from Hold at Argus... Duke Energy (DUK) upgraded to Buy from Neutral at UBS.
News For BSX;CELG;CLF;CS;MXIM;MLNX;PDH;RAS;RPM;VPHM;SYMC;FTI;CVE;GMCR;DUK From The Last 14 Days
Check below for free stories on BSX;CELG;CLF;CS;MXIM;MLNX;PDH;RAS;RPM;VPHM;SYMC;FTI;CVE;GMCR;DUK the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
September 16, 2014
07:58 EDTBSXBoston Scientific product still likely to get nod despite data, says Wells Fargo
Although new data presented at TCT showed that the confirmatory PREVAIL study of Boston Scientific's Watchman device missed both co-primary efficacy endpoints, Wells Fargo still thinks there is a 60%-70% chance of an FDA panel recommending approval of the device on October 8. Wells keeps an Outperform rating on the stock.
07:39 EDTRPMCredit Suisse to hold a conference
Basic Materials Conference to be held in New York on September 16-18.
07:31 EDTCSSoftbank, Yahoo poised to profit from record Alibaba IPO, WSJ reports
Subscribe for More Information
05:33 EDTDUKDuke Energy upgraded to Outperform from Market Perform at Wells Fargo
Subscribe for More Information
September 15, 2014
18:25 EDTSYMCFinjan Holdings provides update on Federal Circuit Ruling in patent case
Finjan Holdings (FNJN) provides an update on the case Finjan, Inc. v. Symantec Corp. (SYMC), Websense (WBSN), Inc., Sophos. This patent infringement suit dates back to a legacy litigation filed on July 12, 2010, in the U.S. District Court for the District of Delaware against Symantec Corp., Websense, Inc., Sophos Inc., et al. During this time, two of the five defendants settled; for the three remaining defendants, Websense, Inc., Sophos Inc., and Symantec Corp., the verdict resulted in a finding of invalidity of certain asserted claims of Finjan's patents, U.S. Patent Nos. 6,092,194 and 6,480,962, and non-infringement of same, against the three parties. Finjan's Appeal Brief was filed on December 10, 2013, and the Oral Argument was heard on September 9, 2014. The Court of Appeals for the Federal Circuit issued a decision, affirming the District Court's prior ruling with no opinion, citing Federal Circuit Rule 36. Rule 36 findings by the Court do not provide any additional insight or context into the Court's decision in the case. This CAFC ruling was the most recent outcome in the process to reverse the lower Court's finding of invalidity on claims in the two patents. The two patents in question are not at issue in any of six currently pending cases in the Northern District of California, including three separate actions involving the three remaining parties in the appeal, noted previously. "While we are disappointed with the Panel's finding, we continue to believe in the Court's ability to adjudicate complicated issues in patent cases," commented Julie Mar-Spinola, VP Legal Operations of Finjan. "The two patents in question represent a small number – two of twenty –currently involved in our licensing and enforcement program related to Finjan's pioneering cybersecurity related technologies." Finjan has also filed patent infringement lawsuits against FireEye, Inc., Blue Coat, Inc., Websense, Inc., Sophos Inc. and Symantec Corp. relating to, collectively, more than 20 patents in the Finjan portfolio. The company will continue to provide timely updates of important events relating to these matters on an on-going basis.
16:08 EDTBSXBoston Scientific says REPRISE II data show sustained safety, performance
New data from the Boston Scientific clinical trial program of the LotusValve System continue to demonstrate strong performance as a less invasive treatment for patients with severe aortic stenosis who are considered high risk for surgical valve replacement. Data from the REPRISE II clinical trial confirmed safety and effectiveness out to one year, with more than 86% of patients exhibiting a complete absence of paravalvular aortic regurgitation and no patients demonstrating moderate or severe paravalvular aortic regurgitation. New data from the REPRISE I and REPRISE II clinical trials were presented at the 26th Transcatheter Cardiovascular Therapeutics meeting, the annual scientific symposium of the Cardiovascular Research Foundation. REPRISE II is an ongoing prospective, single-arm, multi-center study designed to evaluate safety and performance of the Lotus Valve System for symptomatic patients with severe calcific aortic stenosis who are considered high risk for surgical valve replacement. The study enrolled 120 patients at 14 sites in Australia, France, Germany and the UK. In REPRISE II, key one-year results include the following: Mean aortic valve pressure gradient remained low and stable at 12.6 + 5.7 mmHg. More than 86% of patients had no paravalvular aortic regurgitation by independent core lab assessment. In addition, no cases of moderate or severe paravalvular aortic regurgitation occurred. Mild and trace paravalvular aortic regurgitation rates were low at 11.4 and 2.3%, respectively. Cardiovascular mortality rate was 6.7%. Disabling stroke rate was 3.4%. No cases of non-study valve implantation, unplanned use of cardiopulmonary bypass, valve embolization, valve-in-valve or ectopic valve placement occurred.
14:01 EDTDUKDuke Energy signs O&M agreement with Pattern Energy
Duke Energy Renewable Services announced it has signed a long-term agreement to service Pattern Energy Group Inc.'s 283-megawatt Gulf Wind energy project in Armstrong, Texas. Duke Energy Renewable Services will supply operations and maintenance services for three years, beginning in November, with an option for a two-year extension.
09:59 EDTSYMCOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:02 EDTDUKDuke Energy commits $500M to North Carolina solar power expansion
Subscribe for More Information
07:45 EDTBSXCardiovascular Research Foundation to hold a conference
Transcatheter Cardiovascular Therapeutics: TCT 2014 to be held in Washington, D.C. on September 13-17 with some presentations being webcasted. Webcast Link
07:27 EDTCELGIBC Life Sciences to hold a conference
Subscribe for More Information
06:06 EDTSYMCSymantec downgraded to Sector Perform from Outperform at RBC Capital
Subscribe for More Information
September 12, 2014
15:03 EDTBSXSt. Jude Medical pausing Portico sales, implants, says Wells Fargo
Subscribe for More Information
September 11, 2014
14:16 EDTSYMCSymantec downgraded to Hold from Buy at Standpoint Research
September 10, 2014
08:08 EDTCLFCliffs Natural amends credit facilty to allow for $200M share repurchase program
Subscribe for More Information
07:24 EDTSYMCSymantec coverage assumed with a Neutral at MKM Partners
Target $24.
September 9, 2014
09:22 EDTMLNXMellanox storage opportunity underappreciated, says Summit Research
Subscribe for More Information
08:47 EDTDUKDuke Energy management to meet with Deutsche Bank
Subscribe for More Information
07:51 EDTCELGNICE says Abraxane price not justified by limited benefit in pancreatic cancer
Subscribe for More Information
07:08 EDTCVEPeters & Co. Ltd to h old a conference
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use